Breaking News on Pharmaceutical Technology

Latest news headlines

Products

Suppliers

Cash injection for Dengue fever vaccine

24-Jul-2007 - US biotech firm VaxInnate has been awarded a lump sum from the National Institutes of Health (NIH) to support the development of the company's tetravalent Dengue fever vaccine.

Tamiflu caps for kids get EU thumbs up

24-Jul-2007 - Roche has received a positive opinion from EU regulators recommending the approval of low-dose capsules of the blockbuster flu drug Tamiflu (oseltamivir), providing a more convenient dosage form for children.

Sanofi's US facility completed

23-Jul-2007 - Sanofi Pasteur has completed construction of its new facility in the US in a bid to meet an anticipated demand for seasonal influenza vaccine in the future.

MHRA stalls cannabis-based MS drug

23-Jul-2007 - A UK firm developing cannabis-derived multiple sclerosis (MS) treatments has decided to pull an EU application for its lead candidate Sativex, following demands by UK regulators for additional data in support of the treatment.

CABB catches SF-Chem in chlorine combo

23-Jul-2007 - German speciality chemicals firm CABB has scooped up Swiss company SF-Chem in a deal set to create a leading European supplier of chlorine and speciality intermediates.

The 'global disaster' of fake internet pharmacies

19-Jul-2007 - Fake internet pharmacies are a growing "global disaster" with increasingly dangerous consequences, pharmaceutical industry figures say.

Canadians get Naprelan

18-Jul-2007 - Canadians finally have access to the controlled-release formulation of naproxen sodium, which has been on the US market for more than 10 years for the management of osteoarthritis and rheumatoid arthritis.

Biocon targets global cell culture market

18-Jul-2007 - Biocon is targeting the global cell culture market with the production of pharmaceutical-grade insulin as a potent growth factor.

Viral vs. non-viral: The debate

18-Jul-2007 - At a packed out session at last week's Controlled Release Society meeting in the US, two experts battled it out to win one of the key debates in gene delivery: which is superior - viral or non-viral delivery?

Acambis' universal vaccine enters the clinic

18-Jul-2007 - UK firm Acambis has announced that its universal influenza vaccine candidate has entered Phase I trials, hoping to prove a key weapon in the fight against pandemic flu and last-minute production panics.

Expansion of allergen material facility

17-Jul-2007 - Biopol Laboratory is acting to meet the demand of sneezes, itchy eyes and running noses as it consolidates its five allergen production facilities into one main building in Idaho.

Single-shot vaccines on the horizon

17-Jul-2007 - Research being carried out at the University of Utrecht in the Netherlands to replace standard vaccination schedules with a single-shot alternative could do away with the need for repeated jabs.

Bridging the blood brain barrier

16-Jul-2007 - A novel technology set to overcome the challenges of the blood brain barrier is being developed in a bid to open the gates to previously unusable compounds for the treatment of central nervous system (CNS) disorders.

Best foam forward

16-Jul-2007 - An Israeli drug delivery firm is developing a new vaginal drug delivery system, making use of bio-adhesive foams to offer a more convenient and effective treatment option for women with gynaecological complaints.

BioSante adjuvant looks promising

12-Jul-2007 - BioSante Pharmaceuticals' vaccine adjuvant is coming up trumps as vaccine manufacturers race towards finding the most efficient bird flu vaccine.

Generics set to boom

12-Jul-2007 - The European generics market is expected to boom to $35.9bn (€26.1bn) in 2013, according to a Frost & Sullivan report.

AlphaVax awarded grant for adjuvant technology

11-Jul-2007 - US-based AlphaVax has been awarded a $3.6m grant from a US Government health agency to develop a new adjuvant technology for vaccines.

Anticalins look promising

10-Jul-2007 - A new generation of therapeutic protein products has entered the biopharma scene and are proving more efficient than antibodies when using the same drug delivery systems.

Shasun gets the thumbs up

10-Jul-2007 - Indian pharmaceutical manufacturing company Shasun Chemicals and Drugs has now got its eye fully on the US market after recent approval of its new formulation facility in Puducherry.

China to play starring role in AstraZeneca API outsourcing

05-Jul-2007 - AstraZeneca is planning to gradually withdraw from making its own active pharmaceutical ingredients (APIs) and will use China as the pinnacle of its new outsourcing plans.

Ex-UCB unit sells for €0.8bn

05-Jul-2007 - Taminco, UCB's old intermediates and derivatives unit, has been sold at auction to European investment group CVC Capital Partners for €0.8bn.

Initiative launched to tackle ICH

04-Jul-2007 - The International Society for Pharmaceutical Engineering (ISPE) has launched a new initiative to help implement the International Conference on Harmonization (ICH) guidelines.

Australia to increase monoclonal antibody production

04-Jul-2007 - Australia is soon to boast the largest monoclonal antibody production facility in the Southern Hemisphere, which will go some way in alleviating the increasing demand for the biologic agents.

Massive vaccine deal makes Intercell's day

02-Jul-2007 - One of the most significant deals to take place in the vaccine industry in the last ten years was signed late last night between vaccine heavyweight Novartis and biotech firm Intercell.

Prolonged-release schizophrenia drug gets EU approval

02-Jul-2007 - A new and improved extended-release treatment for schizophrenia has been granted marketing authorisation by the European Commission. Invega (paliperidone) is a once-daily formulation that will be marketed by J&J subsidiary, Janssen-Cilag.

Sign up for your free newsletter